Home›Trial›NCT07037277

🔬NCT07037277Phase 3RECRUITING

C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV

Study Summary

The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.

Conditions

HEPATITIS C VIRUS CHRONIC INFECTION Hepatitis C, Chronic Hepatitis C Virus Infection Hepatitis C

Interventions / Drugs

Bemnifosbuvir-Ruzasvir Sofosbuvir-Velpatasvir

View on ClinicalTrials.gov ↗

Sponsor

Atea Pharmaceuticals

Infectious Disease

Study Details

Enrollment880 participants

Primary Completion—

Lead SponsorAtea Pharmaceuticals, Inc.

Data Retrieved2026-04-11 02:55:17.105178+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.